Format

Send to

Choose Destination
Br J Pharmacol. 2000 Feb;129(3):420-3.

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Author information

1
Boehringer Ingelheim Pharma KG, Biberach, Germany. henri.doods@bc.boehringer-ingelheim.com

Abstract

Calcitonin gene-related peptide (CGRP) is one of the most potent endogenous vasodilators known. This peptide is increased during migraine attacks and has been implicated in the pathogenesis of migraine headache. Here we report on the first small molecule selective CGRP antagonist: BIBN4096BS. In vitro, this compound is extremely potent at primate CGRP receptors exhibiting an affinity (Ki) for human CGRP receptors of 14.4 +/- 6.3 (n = 4) pM. In an in vivo model, BIBN4096BS in doses between 1 and 30 micrograms kg-1 (i.v.) inhibited the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys. It is concluded that BIBN4096BS is a potent and selective CGRP antagonist.

PMID:
10711339
PMCID:
PMC1571877
DOI:
10.1038/sj.bjp.0703110
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center